Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study.
Schettini F, Brasó-Maristany F, Pascual T, Lorman-Carbó N, Nucera S, Bergamino M, Galván P, Conte B, Seguí E, García Fructuoso I, Gómez Bravo R, Rodríguez AB, Martínez-Sáez O, Chic N, Vidal M, Adamo B, González-Farre B, Sanfeliu E, Cebrecos I, Mensión E, Oses G, Locci M, Mollà M, Ganau S, Jares P, Vidal-Sicart S, Muñoz M, Prat A. Schettini F, et al. Among authors: martinez saez o. ESMO Open. 2024 Nov 27;9(12):103989. doi: 10.1016/j.esmoop.2024.103989. Online ahead of print. ESMO Open. 2024. PMID: 39608304 Free article.
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance.
Waks AG, Martínez-Sáez O, Tarantino P, Braso-Maristany F, Pascual T, Cortés J, Tolaney SM, Prat A. Waks AG, et al. Among authors: martinez saez o. Nat Rev Clin Oncol. 2024 Nov;21(11):818-832. doi: 10.1038/s41571-024-00939-2. Epub 2024 Sep 13. Nat Rev Clin Oncol. 2024. PMID: 39271787 Review.
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer: A Systematic Review and Meta-Analysis.
Villacampa G, Navarro V, Matikas A, Ribeiro JM, Schettini F, Tolosa P, Martínez-Sáez O, Sánchez-Bayona R, Ferrero-Cafiero JM, Salvador F, Papakonstantinou A, Prat A, Oliveira M, Pascual T. Villacampa G, et al. Among authors: martinez saez o. JAMA Oncol. 2024 Oct 1;10(10):1331-1341. doi: 10.1001/jamaoncol.2024.3456. JAMA Oncol. 2024. PMID: 39207778
Hormone receptor-positive early breast cancer in young women: A comprehensive review.
Walbaum B, García-Fructuoso I, Martínez-Sáez O, Schettini F, Sánchez C, Acevedo F, Chic N, Muñoz-Carrillo J, Adamo B, Muñoz M, Partridge AH, Bellet M, Brasó-Maristany F, Prat A, Vidal M. Walbaum B, et al. Among authors: martinez saez o. Cancer Treat Rev. 2024 Sep;129:102804. doi: 10.1016/j.ctrv.2024.102804. Epub 2024 Jul 14. Cancer Treat Rev. 2024. PMID: 39084152 Review.
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer.
Lorman-Carbó N, Martínez-Sáez O, Fernandez-Martinez A, Galván P, Chic N, Garcia-Fructuoso I, Rodríguez A, Gómez-Bravo R, Schettini F, Blasco P, Castillo O, González-Farré B, Adamo B, Vidal M, Muñoz M, Perou CM, Malumbres M, Gavilá J, Pascual T, Prat A, Brasó-Maristany F. Lorman-Carbó N, et al. Among authors: martinez saez o. Sci Rep. 2024 Jul 11;14(1):16030. doi: 10.1038/s41598-024-67126-2. Sci Rep. 2024. PMID: 38992220 Free PMC article.
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.
Brasó-Maristany F, Ferrero-Cafiero JM, Falato C, Martínez-Sáez O, Cejalvo JM, Margelí M, Tolosa P, Salvador-Bofill FJ, Cruz J, González-Farré B, Sanfeliu E, Òdena A, Serra V, Pardo F, Luna Barrera AM, Arumi M, Guerra JA, Villacampa G, Sánchez-Bayona R, Ciruelos E, Espinosa-Bravo M, Izarzugaza Y, Galván P, Matito J, Pernas S, Vidal M, Santhanagopal A, Sellami D, Esker S, Fan PD, Suto F, Vivancos A, Pascual T, Prat A, Oliveira M. Brasó-Maristany F, et al. Among authors: martinez saez o. Nat Commun. 2024 Jul 11;15(1):5826. doi: 10.1038/s41467-024-50056-y. Nat Commun. 2024. PMID: 38992028 Free PMC article.
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer.
Schettini F, Nucera S, Brasó-Maristany F, De Santo I, Pascual T, Bergamino M, Galván P, Conte B, Seguí E, García Fructuoso I, Gómez Bravo R, Rivera P, Rodríguez AB, Martínez-Sáez O, Ganau S, Sanfeliu E, González-Farre B, Vidal Losada MJ, Adamo B, Cebrecos I, Mension E, Oses G, Jares P, Vidal-Sicart S, Mollà M, Muñoz M, Prat A. Schettini F, et al. Among authors: martinez saez o. ESMO Open. 2024 Jul;9(7):103619. doi: 10.1016/j.esmoop.2024.103619. Epub 2024 Jun 28. ESMO Open. 2024. PMID: 38943737 Free PMC article.
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer.
Marín-Aguilera M, Jares P, Sanfeliu E, Villacampa G, Hernández-Lllán E, Martínez-Puchol AI, Shankar S, González-Farré B, Waks AG, Brasó-Maristany F, Pardo F, Manning DK, Abery JA, Curaba J, Moon L, Gordon O, Galván P, Wachirakantapong P, Castillo O, Nee CM, Blasco P, Senevirathne TH, Sirenko V, Martínez-Sáez O, Aguirre A, Krop IE, Li Z, Spellman P, Metzger Filho O, Polyak K, Michaels P, Puig-Butillé JA, Vivancos A, Matito J, Buckingham W, Perou CM, Villagrasa-González P, Prat A, Parker JS, Paré L. Marín-Aguilera M, et al. Among authors: martinez saez o. ESMO Open. 2024 Mar;9(3):102903. doi: 10.1016/j.esmoop.2024.102903. Epub 2024 Mar 6. ESMO Open. 2024. PMID: 38452436 Free PMC article.
45 results